Two Abstracts Selected for Oral Presentation

Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development

CAMBRIDGE, Mass., June 26, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (MACK), a biopharmaceutical company with a pipeline of eight oncology therapeutics and multiple diagnostics, announced today that two oral presentations and three posters on its Network Biology approach to therapeutic development will be presented at the American Association for Cancer Research (AACR) Special Conference "Chemical Systems Biology: Assembling and Interrogating Computational Models of the Cancer Cell by Chemical Perturbations" being held June 27 -- 30, 2012, at the Marriott Copley Place in Boston, Mass.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-looking statements

Any statements in this press release about Merrimack's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Read the rest here:
Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology ...